Compare Cisco Systems Inc (CSCO) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cisco Systems Inc vs Moderna, Inc. — how do they compare? Cisco Systems Inc trades at $118.39 (market cap $452.96B), while Moderna, Inc. trades at $225 (market cap $78.65B). The key difference: Cisco Systems Inc is far larger — about 5.8× Moderna, Inc.'s market cap, and Cisco Systems Inc pays a 1.46% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cisco Systems Inc for 86 Days and Moderna, Inc. for 59 Days on average.
| CSCO | MRNA | |
|---|---|---|
Market Cap | $452.96B | $78.65B |
Volume | 12,951,578 | 37,373,437 |
Sector | Technology | Health |
52-Week High | $130.00 | $225.00 |
52-Week Low | $67.46 | $22.36 |
Typical Hold Time | 86 Days | 59 Days |
Enterprise Value | $466.58B | $74.80B |
Dividend Yield | 1.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cisco Systems (CSCO) trades at $114.89, down 2.13% on the day, amid a bullish technical outlook supported by moving averages and strong institutional sentiment. The company reported robust Q2 2026 EPS of $1.22, beating estimates, with revenue growth driven by AI networking demand. Analysts maintain a 51.35% buy rating with a $129.77 consensus target, highlighting multi-year growth potential from AI infrastructure and Splunk integration.
The stock presents a favorable risk-reward profile with solid fundamentals, including a 20.95% net margin and consistent earnings beats. Key risks include competitive pressures in AI security and cyclical IT spending. Upside is supported by strong cash flow and strategic partnerships, though valuation multiples like a 34.5 P/E warrant monitoring amid macroeconomic uncertainties.
Moderna (MRNA) trades at $197.00, up 0.26% today, reflecting a strong 2026 rally. The stock is technically bullish, with moving averages signaling strength and key support at $194. Fundamentally, revenue has declined from pandemic peaks to $1.92 billion in 2025, with net losses widening to -$2.82 billion, though recent quarters have beaten EPS estimates. The company's inclusion in the Nasdaq-100 index effective October 9, 2026, adds a positive catalyst. Analyst sentiment is mixed, with a consensus price target of $115.70 but a high target of $245.00, indicating divergent views on valuation after the stock's significant run-up.
The outlook for Moderna hinges on its pipeline beyond COVID-19, particularly cancer vaccines, but high valuation ratios (P/S of 35.08) and persistent losses pose risks. Upside potential exists if new products gain traction, yet investors face volatility from clinical trial outcomes and competitive pressures. The stock's proximity to 52-week highs suggests caution amid profit-taking signals from some analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cisco Systems Inc
Cisco Systems, Inc. provides information technology and networking services. The Company offers enterprise network security, software development, data collaboration, cloud computing, and other related services. Cisco Systems serves customers in the United States.
Read more on CSCO →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
